A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 155 participants.

Also called NCT05941455

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 155 participants (planned count) (from the registry)
Sponsor
Jilin Venus Haoyue Medtech Limited (from the registry)
Registry
  • NCT NCT05941455
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05941455. Allocation not applicable; no masking; primary purpose treatment. Start 2023-10-31 (anticipated); primary completion 2025-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve
Acronym
METASAR
Condition
Aortic Valve Disease
Condition
Cardiovascular Diseases
Intervention (Device)
Venus-Neo Surgical Aortic Valve
Lead sponsor
Jilin Venus Haoyue Medtech Limited (class: industry)

Record details

Record id
cardio:ct-nct05941455
Content hash
afebefdbadd2318e33e1986b56f169484d15366e4245b198bf4a4f25f145b944